We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
Our PCA approach may represent a transformative step in the evolution of regenerative medicine, reducing complexity by temporarily reactivate progenitor cells already located at the tissue target site – and pre-programmed to make specific cell types.
Naturally repairing or reversing damage caused by degenerative disease
Hearing loss caused by damage to the sensory cells of the ear impacts hundreds of millions of people globally. Currently there are no FDA-approved treatments to address the underlying condition.
Carlo Tanzi, Ph.D.
Kendall Investor Relations
Associate Director, Digital and Corporate Communications